Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results o... by Barbara Rossetti, Roberta Gagliardini, Genny Meini, Gaetana Sterrantino, Vincenzo Colangeli, Maria Carla Re, Alessandra Latini, Manuela Colafigli, Francesca Vignale, Stefano Rusconi, Valeria Micheli, Antonio Di Biagio, Giancarlo Orofino, Valeria Ghisetti, Alessandra Fantauzzi, Vincenzo Vullo, Pierfrancesco Grima, Daniela Francisci, Claudio Mastroianni, Andrea Antinori, Michele Trezzi, Lucia Lisi, Pierluigi Navarra, Benedetta Canovari, Antonella D'Arminio Monforte, Silvia Lamonica, Alessandro D'Avino, Maurizio Zazzi, Simona Di Giambenedetto, Andrea De Luca, for GUSTA trial study group

Get full text